| 胰高血糖素样肽1受体激动剂对代谢相关脂肪性肝病作用机制的研究进展 |
| |
| 引用本文： | 李娜,刘佳,王广,谢国敏,曲爱娟,李红梅.胰高血糖素样肽1受体激动剂对代谢相关脂肪性肝病作用机制的研究进展[J].中国动脉硬化杂志,2021,29(5):446-450. |
| |
| 作者姓名： | 李娜 刘佳 王广 谢国敏 曲爱娟 李红梅 |
| |
| 作者单位： | 首都医科大学附属北京朝阳医院内分泌科,北京市 100020;清华大学第一附属医院内分泌科,北京市 100016;首都医科大学基础医学院生理学与病理生理学系 重塑相关心血管疾病教育部重点实验室,北京市 100069 |
| |
| 基金项目： | 国家自然科学基金面上项目(81770792)；北京市自然科学基金B类重点项目(KZ201810025038) |
| |
| 摘 要： | 非酒精性脂肪性肝病(NAFLD)(现已更名为代谢相关脂肪性肝病)是一种以肝实质内脂质过度沉积为特征,常与中心性肥胖、2型糖尿病、胰岛素抵抗、代谢综合征等疾病合并存在,被认为是代谢综合征的肝脏表现。非酒精性脂肪性肝炎(NASH)是一种可能导致肝硬化、肝细胞癌的进行性肝病。目前尚无批准用于治疗NAFLD/NASH的药物。近期研究表明胰高血糖素样肽1(GLP-1)受体激动剂作为降糖药,不仅通过肠促胰素作用改善代谢关键参数间接逆转NAFLD的进展,还直接影响肝细胞脂质代谢、炎症及氧化应激。文章对GLP-1受体激动剂在NAFLD/NASH中的作用及潜在机制进行综述。
|
| 关 键 词： | 代谢相关脂肪性肝病 胰高血糖素样肽1受体激动剂 脂质代谢 自噬 炎症 氧化应激 |
| 收稿时间： | 2020/4/1 0:00:00 |
| 修稿时间： | 2020/6/8 0:00:00 |
Update on glucagon-like peptide-1 receptor agonists in metabolic associated fatty liver disease |
| |
| LI N,LIU Ji,WANG Guang,XIE Guomin,QU Aijuan,LI Hongmei.Update on glucagon-like peptide-1 receptor agonists in metabolic associated fatty liver disease[J].Chinese Journal of Arteriosclerosis,2021,29(5):446-450. |
| |
| Authors: | LI N LIU Ji WANG Guang XIE Guomin QU Aijuan LI Hongmei |
| |
| Affiliation: | Department of Endocrinology, Beijing Chaoyang Hospital Affiliated to Capital Medical University, Beijing 100020, China;Department of Endocrinology, the First Affiliated Hospital of Tsinghua University, Beijing 100016, China;Department of Physiology and Pathophysiology, School of Basic Medical Sciences & Key Laboratory of Remodeling-Related Cardiovascular Diseases, Ministry of Education, Capital Medical University, Beijing 100069, China |
| |
| Abstract: | Nonalcoholic fatty liver disease (NAFLD) is characterized by excessive lipid deposition within the liver parenchyma, and is usually accompanied with obesity, insulin resistance, type 2 diabetes (T2DM), insulin resistance, metabolic syndrome. Recently, NAFLD has been officially renamed metabolic associated fatty liver disease (MAFLD).Nonalcoholic steatohepatitis (NASH) is a progressive liver disease that can lead to cirrhosis, hepatocellular carcinoma.Currently there are no approved drugs available for NAFLD/NASH treatment. Glucagon-like peptide-1 (GLP-1) receptor agonist not only reverses the progression of NAFLD indirectly through an incretin effect that improves key metabolic parameters involved in NAFLD, but also has a direct effect on lipid metabolism, inflammation and oxidative stress of hepatocytes. Herein, this study reviews the effects and potential mechanisms of GLP-1 receptor agonists on nonalcoholic fatty liver disease. |
| |
| Keywords: | metabolic associated fatty liver disease GLP-1 receptor agonist lipid metabolism autophagy inflammation oxidative stress |
| 本文献已被 CNKI 等数据库收录！ |
| 点击此处可从《中国动脉硬化杂志》浏览原始摘要信息 |
|
点击此处可从《中国动脉硬化杂志》下载全文 |
|
